Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010.

The GAAP net loss for the quarter ended March 31, 2011 was $111.8 million, or $0.77 per share, compared to $125.7 million, or $0.96 per share for the quarter ended March 31, 2010 (which included a non-cash charge of $68 million loss from valuation of warrant liability). On a pro-forma basis, excluding non-cash expenses associated with depreciation and amortization, non-cash imputed interest expense, and non-cash deferred stock compensation, Dendreon’s net loss was approximately $85 million or $0.59 per share. Dendreon's total operating expenses for the quarter ended March 31, 2011 were $112.9 million compared to $57.6 million for the three months ended March 31, 2010.

As of March 31, 2011, Dendreon had approximately $779.0 million in cash, cash equivalents, and short-term and long-term investments compared to $277.3 million as of December 31, 2010.

Recent Highlights:

  • In addition to the $28.1 million in revenue in the first quarter, sales of PROVENGE® (sipuleucel-T) in April 2011 were approximately $15 million, reflecting increasing demand and increasing utilization of its newly approved capacity.  Dendreon continues to expect revenue this year of between $350-400 million with approximately half of that anticipated in the fourth quarter.
  • The number of accounts infusing PROVENGE as of March 31, 2011 increased from approximately 50 to approximately 135 and we are on track to meet our goal of 225 sites infusing PROVENGE by the end of Q2.
  • The U.S. Food and Drug Administration (FDA) approved the expanded New Jersey manufacturing facility.  The 36 a
    '/>"/>

  • SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
    2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
    3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
    4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
    5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
    6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
    7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
    8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
    9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
    10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
    11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    (Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
    (Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
    (Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... , BRUSSELS , June 18 ... system) significantly improved wellbeing and daily activities that are often ... presented this week at the 14th International Congress of Parkinson,s ... Additional data from an open-label extension study showed that the ...
    ... NATICK, Massachusetts and NICE, France , ... BSX ) today,announced results from a sub-analysis ... greater clinical benefit from its cardiac resynchronization,therapy defibrillators (CRT-Ds) ... World Congress by Jonathan Steinberg , M.D., Chief ...
    ... of water mysteriously gush out of the desert floor at a ... plant and animal species found nowhere else in the world. ... at Ash Meadows is completing a 15,000-year journey, flowing slowly underground ... government tested nuclear bombs there for four decades, and a crack ...
    Cached Biology Technology:Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 2Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 3Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 4Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 5Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 6Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 7Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 8Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 9Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome 10MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 2MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 3MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men 4
    (Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
    (Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
    (Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
    Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
    ... take-away paper-based food containers (such as pizza boxes) that ... because the containers were made from pulp that contained ... where the test was developed, this use of recycled ... rules. Recycling paper and cardboard is a great ...
    ... Fingerprint Software Enhances Biometric Time Clock Security ... Fingerprint SDK Development, ATLANTA, Nov. 27 ... firm, announced today that Software,Techniques Inc. has ... by integrating M2SYS, Bio-SnapON(TM) solution., Bio-SnapON(TM) ...
    ... Scientists Meet for Global Conference ,On Stem Cell ... Ground-breaking Advances, Pioneering Innovations ,In Cell-Based Therapeutic Approaches ... Research Foundation (CRF) brings experts to New York ... Annual International Conference on Cell Therapy for Cardiovascular ...
    Cached Biology News:New test finds diisobutyl phthalate in some cardboard food packaging -- recycling is the issue 2Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time & Attendance Solutions 2Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 2Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases 3
    Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
    MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
    MAB3246 recognizes the neuro-endocrine specific protein (NSP) C....
    PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
    Biology Products: